Novel Long-Acting Amylin Peptides Show Strong Potential for Obesity and Type 2 Diabetes

The global prevalence of obesity and Type 2 Diabetes (T2D) continues to rise, necessitating innovative therapeutic strategies. Amylin, a neuroendocrine hormone co-secreted with insulin, plays a crucial role in glucose homeostasis by regulating gastric emptying, suppressing post-prandial glucagon secretion, and promoting satiety. However, native amylin's short half-life and dose-limiting gastrointestinal side effects have hindered its widespread clinical application. This research addresses the critical need for developing amylin analogs with improved pharmacokinetic profiles and enhanced tolerability for chronic management of metabolic diseases.

Treatment with Amylin-LP1 demonstrated significant improvements across metabolic parameters. In DIO mice, the 0.1 mg/kg dose led to a 25% reduction in body weight over 8 weeks compared to vehicle, with a 40% decrease in cumulative food intake (p<0.001). ZDF rats treated with 0.1 mg/kg Amylin-LP1 showed a 38% reduction in fasting glucose levels and a 1.8% absolute decrease in HbA1c (p<0.01) after 12 weeks. Insulin sensitivity, as measured by HOMA-IR, improved by 55% in the treated ZDF rats. The most impactful finding was that Amylin-LP1 achieved superior weight loss and glycemic control with a 50% reduction in observed gastrointestinal side effects compared to equipotent doses of native amylin in preliminary tolerability assessments.